Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for ANTH. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: ANTH is a Buy candidate.
ANTH stock price ended at $0 on 星期二, after rising NaN%
On the latest trading day Jan 20, 2026, the stock price of ANTH rose by NaN%, climbing from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. Notably, trading volume dropped by 5.5K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 6.1K shares were traded, equating to a market value of approximately --.